Increase in interleukin-6 levels is related to depressive phenomena in the acute (Relapsing) phase of multiple sclerosis

Journal of Neuropsychiatry and Clinical Neurosciences

Volumn 23, Issue 4, 2011, Pages 442-448

  Koutsouraki, Euphrosyni ^a   Hatzifilipou, Eleni ^a   Michmizos, Dimitrios ^a   Cotsavasiloglou, Christos ^a   Costa, Vassiliki ^a   Baloyannis, Stavros ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DEPRESSION; DISABILITY SEVERITY; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RELAPSE; REMISSION;

EID: 84858067588     PISSN: 08950172     EISSN: 15457222     Source Type: Journal    
DOI: 10.1176/jnp.23.4.jnp442     Document Type: Article

References (30)

1. Harris VK, Sadiq SA: Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision-making. Mol Diagn Ther 2009; 13:225-244.
2. Siegert RJ, Abernethy DA: Depression in multiple sclerosis: a review. J Neurol Neurosurg Psych 2005; 76:469-475.
3. Bagert B, Camplair P, Bourdette D: Cognitive dysfunction in multiple sclerosis: natural history, pathophysiology, and management. CNS Drugs 2002; 16:445-455.
4. Herbert TB, Cohen S: Depression and immunity: a meta-analytic review. Psychol Bull 1993; 113:472-486.
5. Bongioanni P, Mosti S, Romano MR, et al: Increased T-lymphocyte interleukin-6 binding in patients with multiple sclerosis. Eur J Neurol 2000; 7:291-297.
6. Maimone D, Guazzi GC, Annunziata P: IL-6 detection in multiple sclerosis brain. J Neurol Sci 1997; 146:59-65.
7. Serada S, Fujimoto M, Mihara M, et al: IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis. PNAS 2008; 105:9041-9046.
8. Olsson T: Cytokine-producing cells in experimental autoimmune encephalomyelitis and multiple sclerosis. Neurology 1995; 45:11-13.
9. Klein TW: Stress and infection. J Florida Med Assoc 1993; 80:409-411.
10. Frommberger U, Bauer J, Haselbauer P, et al: Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur Arch Psychiatry Clin Neurosci 1997; 247:228-233.
11. Alesci S, Martinez P, Kelkar S, et al: Major depression is associated with significant diurnal elevations in plasma IL-6 levels, a shift of its circadian rhythm, and loss of physiologic complexity in its secretion: clinical implications. J Clin Endocrin Metabol 2005; 90:2522-2530.
12. Basterzi AD, Aydemir C, Kisa C, et al: IL-6 levels decrease with SSRI treatment in patients with major depression. Hum Psychopharmacol 2005; 20:473-476.
13. Howren MB, Lamkin DM, Suls J: Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis Psychosom Med 2009; 71:171-186.
14. Akira S, Kishimoto T, Taga T: Interleukin-6 in biology and medicine. Adv Immunol 1993; 54:1-78.
15. Heinrich PC, Behrmann I, Haan S, et al: Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003; 374:1-20.
16. Hautecoeur P, Forzy G, Gallois P, et al: Variations of IL2, IL6, TNF-alpha plasma levels in relapsing-remitting multiple sclerosis. Act Neuro Belg 1997; 97:240-243.
17. Vink A, Uyttenhove WP: Accessory factors involved in murine T-cell activation: distinct roles of interleukin-6, interleukin-1, and tumor necrosis factor. Eur J Immunol 1990; 20:1-6.
18. Kurtzke JF: Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33:1444-1452.
19. McDonald WI, Compston A, Edan G, et al: Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001; 50:121-127.
20. Mystakidou K, Tsilika E, Parpa E, et al: Beck Depression Inventory: exploring its psychometric properties in a palliativecare population of advanced cancer patients. Eur J Cancer Care (Engl) 2007; 16:244-250.
21. Leonardou A, Zervas Y, Papageorgiou C, et al: Validation of the Edinburgh Postnatal Depression Scale and prevalence of postnatal depression at two months postpartum in a sample of Greek mothers. J Reprod Inf Psychol 2009; 27:28-39.
22. Lykouras E, Ioannidis C, Voulgari A, et al: Depression among general hospital patients in Greece. Acta Psychiatr Scand 1989; 79:148-152.
23. Sullivan MJ, Weinshenker B, Mikail S, et al: Screening for major depression in the early stages of multiple sclerosis. Can J Neurol Sci 1995; 22:228-231.
24. Goldman Consensus Group: The Goldman Consensus Statement on Depression in Multiple Sclerosis. Mult Scler 2005; 11:328-337.
25. Lykouras L, Adrachta D, Kalfakis N, et al: GHQ-28 as an aid to detect mental disorders in neurological inpatients. Acta Psychiatr Scand 1996; 93:212-216.
26. Segopolo MT: A screening instrument for psychological distress in Botswana: validation of the Setswana version of the 28-item General Health Questionnaire. Int J Soc Psychol 2009; 55:149-156.
27. Ginieri-Coccossis M, Triantafillou E, Tomaras V, et al: Quality of life in mentally ill, physically ill, and healthy individuals: the validation of the Greek version of the World Health Organization Quality of Life (WHOQOL-100) Questionnaire. Ann Gen Psychiatry 2009; 8:23
28. Chung MC, Preveza E, Papandreou K, et al: Spinal cord injury, posttraumatic stress, and locus of control among the elderly: a comparison with young and middle-aged patients. Psychiatry 2006; 69:69-80.
29. Garyfallos G, Karastergiou A, Adamopoulou A, et al: Greek version of the General Health Questionnaire: accuracy of translation and validity. Acta Psychiatr Scand 1991; 84:371-378
30. Triantafyllou N, Evangelopoulos ME, Kimiskidis VK, et al: Increased plasma homocysteine levels in patients with multiple sclerosis and depression. Ann Gen Psychiatry 2008; 9:7-17.